Combination Therapy with Enzalutamide and Radium-223 in mCRPC: Insights from the REASSURE Study

Interview: At ESMO 2025, Professor Igle Jan de Jong shared new insights from the REASSURE study, highlighting that the combination of enzalutamide and radium-223 is safe, well-tolerated, and promising for patients with mCRPC.